Tiny Phama Could Benefit From US Anti-Heroin Effort
This article was originally published in Scrip
Executive Summary
A White House-led effort to curb the use of heroin, for which the Obama administration is pumping millions of dollars, could be a boon for a tiny Virginia-based pharmaceutical firm that makes the only FDA-approved naloxone product intended for immediate administration in an emergency situation.